Lung Cancers Today

Dr. Mona JhaveriLung Cancer | November 29, 2023
Dr. Mona S. Jhaveri discusses the importance of Lung Cancer Awareness Month, recent breakthroughs in lung cancer, and more.
View More
Dr. Ofer SharonNon-Small Cell Lung Cancer | November 22, 2023
Dr. Ofer Sharon, CEO of OncoHost, to discusses a predictive biomarker for irAEs in non-small cell lung cancer.
Mark McDonoughNon-Small Cell Lung Cancer | November 21, 2023
Mark McDonough, CEO of ChromaCode, discusses an innovative, high-definition PCR assay for enhanced detection of NSCLC.
Rebecca AraujoNon-Small Cell Lung Cancer | November 17, 2023
In patients with metastatic nonsquamous NSCLC, pembrolizumab plus chemotherapy showed clinical efficacy.
Rob DillardMesothelioma | November 14, 2023
Asbestos exposure led to a higher incidence of asbestos-related lung cancers in naval personnel.
Rob DillardLung Cancer | November 13, 2023
Dr. Melissa Johnson, of Sarah Cannon, discusses lung cancer trials to keep an eye on and unmet needs in lung cancer.
Arun KrishnaNon-Small Cell Lung Cancer | November 9, 2023
Arun Krishna, of AstraZeneca, spoke about the FLAURA2 trial, which showed the efficacy of Tagrisso in the treatment of NSCLC.
Rob DillardNon-Small Cell Lung Cancer | November 7, 2023
Taxus chinensis has significant therapeutic potential in alleviating non-small cell lung cancer.
Bo Wang, MDNon-Small Cell Lung Cancer | November 6, 2023
Drs. Bo Wang and Sheena Bhalla discuss the EVOKE-02 study, which assessed sacituzumab govitecan plus pembrolizumab in NSCLC.
Rob DillardMesothelioma | November 3, 2023
BAP1 immunohistochemistry and p16 (CDKN2A) deletion contribute to providing a definitive diagnosis of mesothelioma.
Rob DillardLung Cancer | November 2, 2023
The ACS has released an update to its lung cancer screening guideline, which applies to nearly five million smokers.
Rob DillardLung Cancer | October 30, 2023
Risk model-based lung cancer screening may reduce racial and ethnic disparities and improve overall screening efficiency.
Rob DillardESMO Congress 2023 | October 26, 2023
Perioperative immunotherapy both before and after surgery significantly improves EFS in operable early-stage NSCLC.
Rob DillardESMO Congress 2023 | October 23, 2023
Immune evasion alterations impact the duration of response to checkpoint inhibitors in patients with metastatic NSCLC.
Rob DillardESMO Congress 2023 | October 20, 2023
Neoadjuvant pembrolizumab in combination with chemotherapy followed by resection and adjuvant pembro improves OS in NSCLC.
Rob DillardESMO Congress 2023 | October 20, 2023
Dostarlimab and chemotherapy combo demonstrates robust safety and efficacy in treating metastatic nonsquamous NSCLC.
Rob DillardNon-Small Cell Lung Cancer | October 17, 2023
The FDA approved pembrolizumab for the neoadjuvant and adjuvant treatment of resectable non-small cell lung cancer.
Rob DillardNon-Small Cell Lung Cancer | October 12, 2023
The FDA approved encorafenib with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer.
Rob DillardLung Cancer | October 6, 2023
A machine learning model that uses 3 variables can predict lung cancer risk and the need for screening.
Rob DillardNon-Small Cell Lung Cancer | October 2, 2023
A liquid biopsy test may determine which patients with NSCLC benefit from targeted radiation.
Latest News

November 30, 2023